Gilead Sciences Inc Total Assets
Gilead Sciences Inc total assets. Based on the latest financial reports, Gilead Sciences Inc (GILD) holds total assets worth $49.36 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Gilead Sciences Inc (GILD) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Gilead Sciences Inc (1990–2025)
Total assets of Gilead Sciences Inc from 1990 to 2025. This chart illustrates how Gilead Sciences Inc's total assets have evolved over time, based on quarterly financial data. See latest Gilead Sciences Inc stock price today for real-time trading data and today's change.
Gilead Sciences Inc - Asset Composition Analysis
Gilead Sciences Inc Total Assets Breakdown (December 2025)
Gilead Sciences Inc total assets breakdown as of December 2025. Gilead Sciences Inc's total assets of $49.36 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.8% |
| Accounts Receivable | $4.91 Billion | 8.3% |
| Inventory | $1.77 Billion | 3.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $16.98 Billion | 28.8% |
| Goodwill | $8.31 Billion | 14.1% |
Asset Composition Trend (1990–2025)
This chart illustrates how Gilead Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GILD net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gilead Sciences Inc's current assets represent 31.1% of total assets in 2025, a decrease from 83.2% in 1990.
- Cash Position: Cash and equivalents constituted 12.8% of total assets in 2025, down from 82.4% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is intangible assets at 28.8% of total assets.
Gilead Sciences Inc Competitors by Total Assets
Key competitors of Gilead Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Sanofi
F:SNW2
|
Germany | €129.79 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.49 Billion |
|
Grifols S.A
F:G0FB
|
Germany | €19.71 Billion |
|
TTK Healthcare Limited
NSE:TTKHLTCARE
|
India | Rs13.29 Billion |
|
Eli Lilly and Company
NYSE:LLY
|
USA | $142.28 Billion |
Gilead Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.32 | 1.37 |
| Quick Ratio | 1.09 | 1.15 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.92 Billion | $3.53 Billion | $3.75 Billion |
Gilead Sciences Inc - Advanced Valuation Insights
This section examines the relationship between Gilead Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.00 |
| Latest Market Cap to Assets Ratio | 3.09 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $59.02 Billion |
| Market Capitalization | $182.40 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Gilead Sciences Inc's assets at a significant premium (3.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Gilead Sciences Inc's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Gilead Sciences Inc (1990–2025)
The table below shows the annual total assets of Gilead Sciences Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $59.02 Billion | +0.05% |
| 2024-12-31 | $58.99 Billion | -5.04% |
| 2023-12-31 | $62.12 Billion | -1.66% |
| 2022-12-31 | $63.17 Billion | -7.04% |
| 2021-12-31 | $67.95 Billion | -0.67% |
| 2020-12-31 | $68.41 Billion | +11.00% |
| 2019-12-31 | $61.63 Billion | -3.22% |
| 2018-12-31 | $63.67 Billion | -9.40% |
| 2017-12-31 | $70.28 Billion | +23.35% |
| 2016-12-31 | $56.98 Billion | +9.91% |
| 2015-12-31 | $51.84 Billion | +49.55% |
| 2014-12-31 | $34.66 Billion | +53.52% |
| 2013-12-31 | $22.58 Billion | +6.30% |
| 2012-12-31 | $21.24 Billion | +22.75% |
| 2011-12-31 | $17.30 Billion | +49.26% |
| 2010-12-31 | $11.59 Billion | +19.53% |
| 2009-12-31 | $9.70 Billion | +39.81% |
| 2008-12-31 | $6.94 Billion | +18.89% |
| 2007-12-31 | $5.83 Billion | +42.80% |
| 2006-12-31 | $4.09 Billion | +8.49% |
| 2005-12-31 | $3.77 Billion | +74.69% |
| 2004-12-31 | $2.16 Billion | +38.67% |
| 2003-12-31 | $1.55 Billion | +20.69% |
| 2002-12-31 | $1.29 Billion | +62.08% |
| 2001-12-31 | $794.79 Million | +17.21% |
| 2000-12-31 | $678.10 Million | +55.24% |
| 1999-12-31 | $436.81 Million | -10.45% |
| 1998-12-31 | $487.80 Million | +38.54% |
| 1997-12-31 | $352.10 Million | +13.32% |
| 1996-12-31 | $310.70 Million | +86.38% |
| 1995-12-31 | $166.70 Million | +62.79% |
| 1994-12-31 | $102.40 Million | -19.12% |
| 1993-12-31 | $126.60 Million | -13.76% |
| 1992-12-31 | $146.80 Million | +35.05% |
| 1991-12-31 | $108.70 Million | +769.60% |
| 1990-12-31 | $12.50 Million | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatiti… Read more